Evaluation of sorafenib in Chinese unresectable hepatocellular carcinoma patients with prior surgery and portal vein tumor thrombosis: A subset analysis of GIDEON study data
The purpose of this study was to examine the safety and efficacy of sorafenib in Chinese patients with unresectable hepatocellular carcinoma. Data of 338 Chinese patients from the Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib study data...
Saved in:
Main Authors: | Sheng-Long Ye, Xiaoping Chen, Jiamei Yang, Ping Bie, Shuijun Zhang, Fengyong Liu, Luming Liu, Jie Zhou, Kefeng Dou, Christina SM Yip, Xiaolei Yang |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2017-03-01
|
Series: | Tumor Biology |
Online Access: | https://doi.org/10.1177/1010428317695030 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Combination therapy of sorafenib and TACE for unresectable HCC: a systematic review and meta-analysis.
by: Lei Liu, et al.
Published: (2014-01-01) -
Antitumor activity of sorafenib on colorectal cancer
by: Turgut Kacan, et al.
Published: (2016-08-01) -
PHARMACOECONOMICAL RESEARCH OF THE USE OF SORAFENIB IN MALIGNANT TUMORS
by: M. Y. Frolov, et al.
Published: (2016-09-01) -
In vivo assessment of pharmacokinetic interactions of empagliflozin and henagliflozin with sorafenib: an animal-based study
by: Wenyu Du, et al.
Published: (2025-07-01) -
Co-Assembled Nanoparticles Comprising Sorafenib and Hederagenin Derivative for Enhanced Anti-Hepatic Fibrosis Activity
by: Lu M, et al.
Published: (2025-07-01)